Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Non-small Cell Lung Cancer NSCLC Clinical Trial

— ORION  

Official title:

A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum-Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03775486
• Other study ID #: D9102C00001
• Secondary ID: 2018-003460-30
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: December 21, 2018
• Est. completion date: September 27, 2024

Study information

• Verified date: January 2024
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients whose disease has not progressed following Standard of Care (SoC) platinum-based chemotherapy with Durvalumab as first-line treatment in patients with Stage IV non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.

Description:

Adult patients with a histologically or cytologically documented advanced NSCLC not amenable to curative surgery or radiation with tumors that lack activation EGFR mutations and ALK fusions are eligible for enrollment. During the initial therapy phase, patients will receive treatment with Durvalumab along with the Investigator's choice of platinum-based doublet therapy for squamous NSCLC (nab-paclitaxel plus carboplatin or gemcitabine plus carboplatin/cisplatin) and non-squamous NSCLC (nab-paclitaxel plus carboplatin or pemetrexed plus carboplatin/cisplatin) for 4 cycles. Patients who have completed 4 cycles and not progressed throughout the initial therapy phase will be randomized in a 1:1 ratio into the maintenance phase of the study to receive either Durvalumab plus placebo or Durvalumab plus Olaparib maintenance therapy. Patients will receive maintenance treatment until specific discontinuation criteria are met, including clinical disease progression (as assessed by the Investigator) or RECIST 1.1-defined radiological Progressive Disease (PD), unacceptable toxicity, and withdrawal of consent. Tumor evaluation scans will be performed until objective disease progression as efficacy assessments. All patients will be followed for survival until the end of the study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 401
• Est. completion date: September 27, 2024
• Est. primary completion date: January 11, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 130 Years

Eligibility

Inclusion Criteria:

• Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation. Patients must have tumors that lack activating EGFR mutations and ALK fusions.
• (WHO)/(ECOG) performance status of 0 or 1
• No prior chemotherapy or any other systemic therapy for Stage IV NSCLC
• Adequate organ and marrow function without blood transfusions in the past 28 days,
• At least 1 tumor lesion, not previously irradiated, that can be accurately measured as per RECIST 1.1.

Key Inclusion criteria for randomization to maintenance treatment:

• Documented radiographic evidence of CR, PR, or Stable Disease (SD) as per Investigator-assessed RECIST 1.1 following 4 cycles of platinum-based chemotherapy.
• Creatinine Clearance (CrCl) =51 mL/min calculated by the investigator or designee using the Cockcroft-Gault equation or measured by 24-hour urine collection.
• Ability to swallow whole oral medications.
• All patients must provide a formalin-fixed, paraffin embedded tumor sample for tissue-based immunohistochemistry staining and DNA sequencing to determine PD-L1 expression, HRRm status, and other correlatives: either newly acquired or archival tumor samples (<3 years old) are acceptable. If available, a newly acquired tumor biopsy, collected as part of routine clinical practice, is preferred. If not available, an archival sample taken <3 years prior to screening is acceptable. If both an archival sample and a fresh tumor biopsy sample are available, both samples should be submitted for analysis and must be submitted as different samples using different accession numbers. Slides from different blocks cannot be mixed and submitted with the same kit. Exclusion criteria
• Mixed small-cell lung cancer and sarcomatoid variant NSCLC histology.
• Prior exposure to any chemotherapy agents (except chemotherapy or chemoradiation for non-metastatic disease), polyadenosine 5'diphosphoribose [poly (ADP ribose)] polymerase (PARP) therapy, or immunomediated therapy
• Active or prior documented autoimmune or inflammatory disorders.
• Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.
• Current or prior use of immunosuppressive medication within 14 days before the first dose of Investigational Product (IP)
• untreated (CNS) metastases and/or carcinomatous meningitis
• Active infection.

Exclusion criteria to be randomized to maintenance treatment:

• Inability to complete 4 cycles of platinum-based chemotherapy for any reason or discontinuation of Durvalumab during initial therapy.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer NSCLC

Intervention

Drug:
• Durvalumab
Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
• Placebo for Olaparib
Matching tablet
• Olaparib
150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
• Nab-paclitaxel+carboplatin
Standard of Care chemotherapy (squamous and non-squamous patients)
• Gemcitabine+carboplatin
Standard of Care chemotherapy (squamous patients only)
• Pemetrexed+carboplatin
Standard of Care chemotherapy (non-squamous patients only)
• Gemcitabine+cisplatin
Standard of Care chemotherapy (squamous patients only)
• Pemetrexed+cisplatin
Standard of Care chemotherapy (non-squamous patients only)

Locations

Country	Name	City	State
Belgium	Research Site	Aalst
Belgium	Research Site	Leuven
Belgium	Research Site	Roeselare
Hungary	Research Site	Budapest
Hungary	Research Site	Budapest
Hungary	Research Site	Debrecen
Hungary	Research Site	Deszk
Hungary	Research Site	Farkasgyepü
Hungary	Research Site	Törökbálint
India	Research Site	Ahmedabad
India	Research Site	Ahmedabad
India	Research Site	Jamnagar
India	Research Site	Kochi
India	Research Site	Mysuru
India	Research Site	Nashik
India	Research Site	Nashik
India	Research Site	Pune
India	Research Site	Thiruvananthapuram
Japan	Research Site	Chuo-ku
Japan	Research Site	Kanazawa-shi
Japan	Research Site	Kurume-shi,
Japan	Research Site	Matsuyama-shi
Japan	Research Site	Nagoya-shi
Japan	Research Site	Sendai-shi
Japan	Research Site	Sunto-gun
Japan	Research Site	Ube-shi
Korea, Republic of	Research Site	Dongjakgu
Korea, Republic of	Research Site	Goyang-si
Korea, Republic of	Research Site	Seodaemun-gu
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Suweonsi Paldalgu
Mexico	Research Site	Chihuahua
Mexico	Research Site	Culiacan
Mexico	Research Site	San Luis Potosí
Netherlands	Research Site	Blaricum
Netherlands	Research Site	Harderwijk
Netherlands	Research Site	Tilburg
Poland	Research Site	Bialystok
Poland	Research Site	Lódz
Poland	Research Site	Poznan
Poland	Research Site	Prabuty
Russian Federation	Research Site	Arkhangelsk
Russian Federation	Research Site	Chelyabinsk
Russian Federation	Research Site	Kursk
Russian Federation	Research Site	Moscow
Russian Federation	Research Site	Nal'chik
Russian Federation	Research Site	P. Herzen Moscow Oncology Rese
Russian Federation	Research Site	Sochi
Russian Federation	Research Site	St. Petersburg
Russian Federation	Research Site	Yaroslavl
Ukraine	Research Site	Dnipro
Ukraine	Research Site	Kharkiv Region
Ukraine	Research Site	Kirovohrad
Ukraine	Research Site	Odesa
Ukraine	Research Site	Uzhhorod
Ukraine	Research Site	Zaporizhzhia
United Kingdom	Research Site	Dundee
United Kingdom	Research Site	Hull
United States	Research Site	Bethlehem	Pennsylvania
United States	Research Site	Bonita Springs	Florida
United States	Research Site	Chattanooga	Tennessee
United States	Research Site	Houston	Texas
United States	Research Site	Kansas City	Missouri
United States	Research Site	Nashville	Tennessee
United States	Research Site	Saint Petersburg	Florida
United States	Research Site	Tallahassee	Florida
United States	Research Site	West Palm Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Belgium,  Hungary,  India,  Japan,  Korea, Republic of,  Mexico,  Netherlands,  Poland,  Russian Federation,  Ukraine,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free Survival	Progression-free survival (PFS) based on investigator assessments according to Response Evaluation Criteria in Solid Tumours version 1.1.; PFS is defined as time from date of randomization until the date of objective radiological disease progression using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) or death (by any cause in the absence of progression).	From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Secondary	Overall Survival	Overall survival (OS) across the maintenance phase.; OS is defined as time from date of randomization until the date of death by any cause	From randomization until the date of death due to any cause, up to 18 months.
Secondary	Objective Response Rate	Objective response rate (ORR) defined as number of participants with complete response (CR) or partial response (PR) after randomization	From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Secondary	Duration of Response	Duration of response (DoR) defined as time from the date of first documented response following randomization until the first date of documented progression or death in the absence of disease progression.; Percentage of participants remaining in response at 3, 6, 9 and 12 months estimated using the Kaplan-Meier method.	From date of first documented response until objective radiological disease progression or death, up to 18 months.
Secondary	Progression-free Survival in Homologous Recombination Repair Related Gene Mutation (HRRm) Population	Progression-free survival in homologous recombination repair related gene mutation (HRRm) population defined as time from date of randomization until the date of objective radiological disease progression in HRRm population using Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) or death (by any cause in the absence of progression).	From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Secondary	Concentration of Durvalumab	Concentration (pharmacokinetics) of durvalumab	Assessed from start of initial therapy up to 2 years.
Secondary	Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13	Disease-related symptoms assessed by change from baseline (for maintenance phase) in EORTC QLQ-LC13. Average adjusted mean over first 11 cycles is presented.; The EORTC QLQ-LC13 was scored according to the published scoring manual. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales in the EORTC QLQ-LC13. Higher scores on symptom scales represent greater symptom severity.	From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Secondary	Time to Deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13	Disease-related symptoms assessed by time to deterioration (for maintenance phase) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13.; Symptom deterioration is defined as an increase in the score from baseline of less than or equal to 10) that is confirmed at a subsequent assessment, or death (by any cause) in the absence of a clinically meaningful symptom deterioration.; NA is "not applicable". The upper confidence limit was not calculable because of an insufficient number of participants with events.	From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months
Secondary	Change From Baseline in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30	Disease-related symptoms and health-related quality of life (HRQoL) assessed by change from baseline (for maintenance phase) in EORTC QLQ-C30. Average adjusted mean over first 11 cycles is presented.; The EORTC QLQ-C30 was scored according to the published scoring manual. An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales, each of the function scales, and the global health status/QoL scale in the EORTC QLQ-C30. Higher scores on the global health status and function scales indicate better health status/function.; A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / quality of life (QoL) represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.	Includes all assessments occurring within the first 12 months of randomization or until disease progression, up to 18 months.
Secondary	Time to Deterioration in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30	Disease-related symptoms and health-related quality of life (HRQoL) assessed by time to deterioration (for maintenance phase) in EORTC QLQ-C30.; NA is "not applicable". The upper confidence limit was not calculable because of an insufficient number of participants with events.	From randomization until date of first symptom deterioration that is confirmed, up to 18 months.
Secondary	Presence of Anti-drug Antibodies (ADAs) for Durvalumab	Presence of anti-drug antibodies (ADAs) for durvalumab, as assessed at 3, 6, 12, 16 and 20 weeks after start of treatment and every 12 weeks thereafter until 3 and 6 months after last dose of durvalumab	Assessed from start of initial therapy up to 2 years.
Secondary	Number of Participants With Treatment-Related Adverse Events	Number of Participants with Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE)	From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months

External Links

•   Related Info
•   Related Info
•   Related Info